...
机译:血清可溶性白介素2受体(sIL-2R)水平决定了侵袭性非霍奇金淋巴瘤患者的临床结局:结合国际预后指数
First Department of Internal Medicine Gifu University Graduate School of MedicineFirst Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
Department of Clinical Laboratory Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of MedicineFirst Department of Internal Medicine Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
Department of Cellular Pathology Gifu University Graduate School of Medicine;
Department of Clinical Laboratory Gifu University Graduate School of Medicine;
First Department of Internal Medicine Gifu University Graduate School of Medicine;
Soluble interleukin-2 receptor (sIL-2R); International Prognostic Index (IPI); Prognostic factor; Non-Hodgkin’s lymphoma;
机译:血清可溶性白介素2受体(sIL-2R)的水平决定了侵袭性非霍奇金淋巴瘤患者的临床结局:结合国际预后指数。
机译:血清可溶性白介素2受体(sIL-2R)是未明确的外周T细胞淋巴瘤(PTCL-U)患者的极强预后因素。
机译:侵袭性非霍奇金淋巴瘤和高危国际预后指数(IPI 3)患者进行一线强化序贯化疗(ISC)后的临床结果:两项连续的ISC试验的最终生存率分析。
机译:原发性乳腺癌患者术前血清CA15-3,CEA和TPS水平的临床和预后意义
机译:非霍奇金淋巴瘤的老年患者的白细胞生长因子的临床结果和成本效益:基于大量人群的研究结果。
机译:侵袭性非霍奇金淋巴瘤患者中高血清白介素6和血管内皮生长因子水平是否有用作为预后指标?
机译:血清可溶性FAS级别决定了患有侵略性非霍奇金淋巴瘤患者的临床症状和结果